These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 39080745

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.
    Krishnan A, Schneider CV, Hadi Y, Mukherjee D, AlShehri B, Alqahtani SA.
    Diabetologia; 2024 Mar; 67(3):483-493. PubMed ID: 38117293
    [Abstract] [Full Text] [Related]

  • 4. Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality.
    Dicker D, Sagy YW, Ramot N, Battat E, Greenland P, Arbel R, Lavie G, Reges O.
    JAMA Netw Open; 2024 Jun 03; 7(6):e2415392. PubMed ID: 38848064
    [Abstract] [Full Text] [Related]

  • 5. Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.
    Banerjee M, Maisnam I, Mukhopadhyay S.
    Cardiovasc Drugs Ther; 2024 Aug 03; 38(4):739-746. PubMed ID: 36696050
    [Abstract] [Full Text] [Related]

  • 6. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
    Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R, Renoux C, Suissa S, Azoulay L.
    BMJ; 2024 Apr 25; 385():e078242. PubMed ID: 38663919
    [Abstract] [Full Text] [Related]

  • 7. Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.
    Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC.
    JAMA Netw Open; 2024 Aug 01; 7(8):e2427258. PubMed ID: 39133485
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
    Anyanwagu U, Mamza J, Mehta R, Donnelly R, Idris I.
    Heart; 2016 Oct 01; 102(19):1581-7. PubMed ID: 27217068
    [Abstract] [Full Text] [Related]

  • 10. The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease.
    Lin Y, Wang TH, Tsai ML, Wu VC, Tseng CJ, Lin MS, Li YR, Chang CH, Chou TS, Tsai TH, Yang NI, Hung MJ, Chen TH.
    Cardiovasc Diabetol; 2023 Mar 17; 22(1):60. PubMed ID: 36932379
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study.
    Peng ZY, Yang CT, Lin WH, Yao WY, Ou HT, Kuo S.
    Cardiovasc Diabetol; 2023 Oct 04; 22(1):272. PubMed ID: 37794465
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.
    Cao H, Liu T, Wang L, Ji Q.
    Diabetes Obes Metab; 2022 Aug 04; 24(8):1448-1457. PubMed ID: 35665989
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
    Lugner M, Sattar N, Miftaraj M, Ekelund J, Franzén S, Svensson AM, Eliasson B.
    Cardiovasc Diabetol; 2021 Mar 22; 20(1):67. PubMed ID: 33752680
    [Abstract] [Full Text] [Related]

  • 20. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E, Dicembrini I, Nreu B, Monami M.
    Diabetes Obes Metab; 2020 Feb 22; 22(2):203-211. PubMed ID: 31595657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.